Publications

Frumm SM, Brondfield S. Medical student motivation in specialised contexts. The clinical teacher. 2023. PMID: 38158828

Wintering A, Hecht A, Meyer J, Wong EB, Hübner J, Abelson S, Feldman K, Kennedy VE, Peretz CAC, French DL, Maguire JA, Jobaliya C, Vasquez MR, Desai S, Dulman R, Nemecek E, Haines H, Hammad M, El Haddad A, Kogan SC, Abdullaev Z, Chehab FF, Tasian SK, Smith CC, Loh ML, Stieglitz E. LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia. Haematologica. 2023. PMID: 38152053

Sweeney PL, Suri Y, Basu A, Koshkin VS, Desai A. Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma. Cancer drug resistance (Alhambra, Calif.). 2023. PMID: 38239394

Grivas P, Koshkin VS, Chu X, Cole S, Jain RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, Woo B, Li-Ning-Tapia E, Hahn NM, Carducci MA. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy. European urology oncology. 2023. PMID: 38155060

Luo J, Sanchez M, Lee E, Hertzler H, Luong N, Mazzola E, Finstein B, Tamen R, Brisbane G, Nguyen T, Paik PK, Chaft JE, Cheng ML, Khalil H, Piha-Paul SA, Sholl LM, Nishino M, Jänne PA, DuBois SG, Hanna GJ, Shapiro GI, French CA. Initial chemotherapy for locally advanced and metastatic NUT carcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023. PMID: 38154515

Lu L, Gou X, Tan SK, Mann SI, Yang H, Zhong X, Gazgalis D, Valdiviezo J, Jo H, Wu Y, Diolaiti ME, Ashworth A, Polizzi NF, DeGrado WF. De novo design of drug-binding proteins with predictable binding energy and specificity. bioRxiv : the preprint server for biology. 2023. PMID: 38187746

Rugo HS, Van Poznak CH, Neven P, Danielewicz I, Lee SC, Campone M, Chik JYK, Vega Alonso E, Naume B, Brain E, Siegel JM, Li R, Uema D, Wagner VJ, Coleman RE. Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials. Breast cancer research and treatment. 2023. PMID: 38123789

Khanna V, Lu R, Kumar J, Molina A, Stehr H, Spiteri E, Spinner M, Silva O, Fernandez-Pol S, Tan B, Greenberg PL. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms. Leukemia Research. 2023. PMID: 38154193

Kennedy VE, Smith CC. FLT3 targeting in the modern era: from clonal selection to combination therapies. International journal of hematology. 2023. PMID: 38112995

Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O'Day S. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Research Communications. 2023. PMID: 38115208

Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, Kang H, Monga V, Nath R, Palmisiano N, Babbar N, Sun W, Hanna GJ. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study. Oral oncology. 2023. PMID: 38118249

Kaidar-Person O, Meattini I, Boersma LJ, Becherini C, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Rugo HS, Del Mastro L, Gennari A, Isacke CM, Vestmø Maraldo M, Marangoni E, Nader Marta G, Mjaaland I, Salvestrini V, Spanic T, Visani L, Morandi A, Lambertini M, Livi L, Coles CE, Poortmans P, Offersen BV. Essential requirements for reporting radiation therapy in breast cancer clinical trials: an international multi-disciplinary consensus endorsed by the European SocieTy for Radiotherapy and Oncology (ESTRO). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2023. PMID: 38122852

Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Yee D, Berry DA, Esserman LJ. Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023. PMID: 38109213

Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN, Chan E, Meher N, Bidlingmaier S, Su Y, Dhrona S, Geng H, Sarin V, VanBrocklin HF, Wilson DM, He J, Zhang L, Steri V, Wong SW, Martin TG, Seo Y, Liu B, Wiita AP, Flavell RR. CD46-targeted theranostics for Positron Emission Tomography and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023. PMID: 38109209

Emperumal CP, Villa A, Hwang C, Oh D, Fong L, Aggarwal R, Keenan BP. Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer. Clinical genitourinary cancer. 2023. PMID: 38185609

Le Bryan Khuong, Alan Paciorek, Farhana Moon, Heath Courtney Lawhn, Thomas Hope, Nicholas Fidelman, Claire Mulvey, Sheila Lindsay, Li Zhang¬, Eric Nakakura, Nancy Joseph, Emily K. Bergsland. Comparison of well-differentiated gastroenteropancreatic grade 3 neuroendocrine tumors (G3NETS): de novo and in the setting of apparent grade progression over time. Endocrine Abstracts. 2023. PMID:

Claire K. Mulvey, Alan Paciorek, Paige Steiding, Farhana Moon, Li Zhang, Emily K. Bergsland. Quality of life differs by age and sex for participants with advanced neuroendocrine neoplasms in the eNET study. Endocrine Abstracts. 2023. PMID:

Alan Paciorek, Farhana Moon, Le Bryan Khuong, Li Zhang, Paige Steiding, Emily Bergsland, Claire Mulvey. Rising incidence of bronchopulmonary neuroendocrine tumors. Endocrine Abstracts. 2023. PMID:

Yazdani A, Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanof H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, Shen JPYC, Lee MS, Kopetz S, Nixon AB, Bertagnolli MM, Perou CM, Innocenti F. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy. Research square. 2023. PMID: 38168324

Zhu X, Koshkin VS. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer. Med (New York, N.Y.). 2023. PMID: 38128535